Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Stevanato Group S.p.A. (NYSE:STVN) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Stevanato Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Stevanato Group has a “Moderate Buy” consensus rating from eight analysts: four recommend holding the stock, two rate it a buy, and two rate it a strong buy. Recent coverage from UBS and Deutsche Bank was neutral/hold, with UBS setting a €23 price target.
  • The shares opened at €19.60, with a market capitalization of about $5.94 billion and a price-to-earnings ratio of 35. The stock has traded between €12.89 and €27.99 over the past year.
  • Stevanato Group slightly missed quarterly earnings expectations, reporting €0.14 EPS versus the €0.15 consensus, while revenue reached €302 million. Insiders sold 21,926 shares worth approximately $459,738 over the past 90 days, although several institutional investors increased their holdings.
  • Get every upgrade, downgrade, and earnings report on Stevanato Group as it happens. Lock in MarketBeat All Access for $149 a year through October 30.

Shares of Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company.

A number of brokerages have recently weighed in on STVN. UBS Group started coverage on Stevanato Group in a research report on Wednesday, September 9th. They set a "neutral" rating and a $23.00 target price on the stock. Weiss Ratings raised shares of Stevanato Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Stevanato Group in a research report on Wednesday, October 7th. They issued a "hold" rating for the company.

Get Our Latest Stock Report on Stevanato Group

Stevanato Group Stock Performance

Shares of Stevanato Group stock opened at €19.60 on Monday. The business has a 50-day simple moving average of €20.76 and a 200 day simple moving average of €19.02. Stevanato Group has a one year low of €12.89 and a one year high of €27.99. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The firm has a market capitalization of $5.94 billion, a price-to-earnings ratio of 35.00, a PEG ratio of 1.60 and a beta of 0.78.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported €0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of €0.15 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. The firm had revenue of €302.00 million during the quarter. On average, research analysts anticipate that Stevanato Group will post 0.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Stevanato Group

In other news, Director Elisabetta Magistretti sold 2,045 shares of the business's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €41,084.05. Following the completion of the sale, the director directly owned 2,930 shares of the company's stock, valued at €58,863.70. The trade was a 41.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mauro Stocchi sold 13,649 shares of the company's stock in a transaction dated Monday, September 28th. The stock was sold at an average price of €21.50, for a total transaction of €293,453.50. Following the completion of the sale, the insider owned 400,000 shares in the company, valued at €8,600,000. This represents a 3.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,926 shares of company stock valued at $459,738 over the last ninety days.

Hedge Funds Weigh In On Stevanato Group

Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC raised its stake in shares of Stevanato Group by 131.2% in the second quarter. Squarepoint Ops LLC now owns 193,311 shares of the company's stock worth $3,493,000 after purchasing an additional 109,702 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Stevanato Group during the second quarter valued at approximately $22,621,000. Confluence Investment Management LLC purchased a new position in shares of Stevanato Group during the second quarter valued at approximately $6,062,000. Conestoga Capital Advisors LLC boosted its position in shares of Stevanato Group by 7.6% during the first quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company's stock valued at $116,762,000 after buying an additional 602,050 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in Stevanato Group by 15.8% during the first quarter. Royal Bank of Canada now owns 421,696 shares of the company's stock worth $5,798,000 after buying an additional 57,536 shares in the last quarter.

About Stevanato Group

(Get Free Report)

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.

Further Reading

Analyst Recommendations for Stevanato Group (NYSE:STVN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stevanato Group Right Now?

Before you consider Stevanato Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.

While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines